Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2012

01.10.2012 | Reproductive Medicine

A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest® when used for luteal phase support in ICSI treatment

verfasst von: Malek-Mansour Aghsa, Haleh Rahmanpour, Maryam Bagheri, Fatemeh Davari-Tanha, Reza Nasr

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study compares the efficacy, side effects and patient convenience of vaginal and rectal routes of administration of progesterone suppositories (Cyclogest) when used for luteal phase support during in vitro fertilization cycles, through the use of antagonist protocols.

Methods

147 patients who underwent intra-cytoplasmic sperm injection cycle were randomized on the day of the embryo transfer (ET) by a computer-generated randomization program to receive 400 mg of Cyclogest either vaginally or rectally twice daily for up to 8 weeks. A pregnancy test was conducted 2 weeks after embryo transfer. If the pregnancy test was negative, the application was discontinued. On day 14th after embryo transfer, patient’s acceptability and side effects were assessed using a questionnaire which was given to the patients on the day of ET prior to performing the pregnancy test. The clinical pregnancy rate at the 8th week of gestation and the level of luteal progesterone were evaluated.

Results

There were no substantial differences in the demographics or other characteristics between the two groups. There were no significant differences in serum P concentration 6 days after ET, the clinical pregnancy and abortion rates. The difficulty of administration route, the discomforts experienced following administration, and the proportion leaking out on the 14th day were similar between the two groups. Significantly more patients administering the medication per vagina had perineal irritation (21.3 vs. 2.2 %). The prevalence of tenesmus (35.1 vs. 21.1 %) and rectal itching (26.7 vs. 2.8 %) were significantly more in rectal route.

Conclusions

This study demonstrates that the efficacy of Cyclogest is similar when administered via both the vaginal and rectal routes. Although their side effects differ, the ease of administration for patients and their preference are similar.
Literatur
1.
Zurück zum Zitat Hubayter ZR, Muasher SJ (2008) Luteal supplementation in vitro fertilization: more questions than answers. Fertil Steril 89:749–758PubMedCrossRef Hubayter ZR, Muasher SJ (2008) Luteal supplementation in vitro fertilization: more questions than answers. Fertil Steril 89:749–758PubMedCrossRef
2.
Zurück zum Zitat Dal Prato L, Borini A (2005) Use of antagonists in ovarian stimulation protocols. Reprod Biomed Online 10:330–338PubMedCrossRef Dal Prato L, Borini A (2005) Use of antagonists in ovarian stimulation protocols. Reprod Biomed Online 10:330–338PubMedCrossRef
3.
Zurück zum Zitat Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) Update of luteal phase support in stimulated ICSI cycles. Hum Reprod Update 13:581–590PubMedCrossRef Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P (2007) Update of luteal phase support in stimulated ICSI cycles. Hum Reprod Update 13:581–590PubMedCrossRef
4.
Zurück zum Zitat Fatemi HM (2009) The luteal phase after 3 decades of IVF: what do we know? Reprod Biomed Online 19:4331PubMedCrossRef Fatemi HM (2009) The luteal phase after 3 decades of IVF: what do we know? Reprod Biomed Online 19:4331PubMedCrossRef
5.
Zurück zum Zitat Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM (2012) The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 24:134–141PubMedCrossRef Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM (2012) The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 24:134–141PubMedCrossRef
6.
Zurück zum Zitat Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P (1998) The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 70:357–359PubMedCrossRef Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A, Devroey P (1998) The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 70:357–359PubMedCrossRef
7.
Zurück zum Zitat Kolibianakis EM, Devroey P (2002) The luteal phase after ovarian stimulation. Reprod Biomed Online 5 Suppl 1 (3):26–35 Kolibianakis EM, Devroey P (2002) The luteal phase after ovarian stimulation. Reprod Biomed Online 5 Suppl 1 (3):26–35
8.
Zurück zum Zitat Fauser BC, Devroey P (2003) Reproductive biology and ICSI: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14:236–242PubMedCrossRef Fauser BC, Devroey P (2003) Reproductive biology and ICSI: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14:236–242PubMedCrossRef
9.
Zurück zum Zitat Bahceci M, Ulug U (2008) Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyper-stimulation for ICSI with ICSI using GnRH antagonist. J Assist Reprod Genet 25:499–502PubMedCrossRef Bahceci M, Ulug U (2008) Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyper-stimulation for ICSI with ICSI using GnRH antagonist. J Assist Reprod Genet 25:499–502PubMedCrossRef
10.
Zurück zum Zitat ASRM Practice Committee (2008) Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. ASRM Practice Committee Position Statement. Fertil Steril 90:S150–S153 ASRM Practice Committee (2008) Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. ASRM Practice Committee Position Statement. Fertil Steril 90:S150–S153
11.
Zurück zum Zitat Ng EHY, Chan CC, Tang OS, Ho PC (2007) A randomized comparison of side effects and patient convenience between Cyclogest1 suppositories and Endometrin1 tablets used for luteal phase support in ICSI treatment. Eur J Obstet Gynecol Reprod Biol 131:182–188PubMedCrossRef Ng EHY, Chan CC, Tang OS, Ho PC (2007) A randomized comparison of side effects and patient convenience between Cyclogest1 suppositories and Endometrin1 tablets used for luteal phase support in ICSI treatment. Eur J Obstet Gynecol Reprod Biol 131:182–188PubMedCrossRef
12.
Zurück zum Zitat Daya S, Gunby J (2004) Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev CD004830 Daya S, Gunby J (2004) Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev CD004830
13.
Zurück zum Zitat Nosarka S, Kruger T, Siebert I, Grove D (2005) Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol Obstet Invest 60:67–74PubMedCrossRef Nosarka S, Kruger T, Siebert I, Grove D (2005) Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol Obstet Invest 60:67–74PubMedCrossRef
14.
Zurück zum Zitat Soliman S, Daya S, Collins J, Hughes EG (1994) The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril 61:1068–1076PubMed Soliman S, Daya S, Collins J, Hughes EG (1994) The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil Steril 61:1068–1076PubMed
15.
Zurück zum Zitat Araujo E, Bernadini L, Frederick JL, Asch RH, Balmaceda JP (1994) Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal phase support in assisted reproduction. J Assist Reprod Genet 11:74–78PubMedCrossRef Araujo E, Bernadini L, Frederick JL, Asch RH, Balmaceda JP (1994) Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal phase support in assisted reproduction. J Assist Reprod Genet 11:74–78PubMedCrossRef
16.
Zurück zum Zitat Levine H, Watson N (2000) Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus Prometrium administered orally in postmenopausal women (3). Fertil Steril 73:516–521PubMedCrossRef Levine H, Watson N (2000) Comparison of the pharmacokinetics of crinone 8 % administered vaginally versus Prometrium administered orally in postmenopausal women (3). Fertil Steril 73:516–521PubMedCrossRef
17.
Zurück zum Zitat Tavaniotou A, Smitz J, Bourgain C, Devroey P (2000) Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 6:139–148PubMedCrossRef Tavaniotou A, Smitz J, Bourgain C, Devroey P (2000) Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 6:139–148PubMedCrossRef
18.
Zurück zum Zitat Penzias AS, Alper MM (2003) Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online 6:287–295PubMedCrossRef Penzias AS, Alper MM (2003) Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod Biomed Online 6:287–295PubMedCrossRef
19.
Zurück zum Zitat Schoolcraft WB, Hesla JS, Gee MJ (2000) Experience with progesterone gel for luteal support in a highly successful ICSI programme. Hum Reprod 15:1284–1288PubMedCrossRef Schoolcraft WB, Hesla JS, Gee MJ (2000) Experience with progesterone gel for luteal support in a highly successful ICSI programme. Hum Reprod 15:1284–1288PubMedCrossRef
20.
Zurück zum Zitat Chakmakjian ZH, Zachariah NY (1987) Bioavailability of progesterone with different modes of administration. J Reprod Med 32:443–448PubMed Chakmakjian ZH, Zachariah NY (1987) Bioavailability of progesterone with different modes of administration. J Reprod Med 32:443–448PubMed
21.
Zurück zum Zitat Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, Trew G (2005) Day 14 maternal serum progesterone levels predict pregnancy outcome in ICSI/ICSI treatment cycles: a prospective study. Hum Reprod 20:741–746PubMedCrossRef Ioannidis G, Sacks G, Reddy N, Seyani L, Margara R, Lavery S, Trew G (2005) Day 14 maternal serum progesterone levels predict pregnancy outcome in ICSI/ICSI treatment cycles: a prospective study. Hum Reprod 20:741–746PubMedCrossRef
22.
Zurück zum Zitat Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P (2000) Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod 15(Suppl 1):129–148PubMedCrossRef Posaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P (2000) Progesterone for the luteal support of assisted reproductive technologies: clinical options. Hum Reprod 15(Suppl 1):129–148PubMedCrossRef
23.
Zurück zum Zitat Moyer DL, de Lignieres B, Driguez P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59:992–997PubMed Moyer DL, de Lignieres B, Driguez P, Pez JP (1993) Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 59:992–997PubMed
24.
Zurück zum Zitat Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B (2011) Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 95:1961–1965PubMedCrossRef Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B (2011) Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril 95:1961–1965PubMedCrossRef
25.
Zurück zum Zitat Kimzey LM, Gumowski J, Merriam GR, Grimes GJ Jr, Nelson LM (1991) Absorption of micronized progesterone from a non-liquefying vaginal cream. Fertil Steril 56:995–996PubMed Kimzey LM, Gumowski J, Merriam GR, Grimes GJ Jr, Nelson LM (1991) Absorption of micronized progesterone from a non-liquefying vaginal cream. Fertil Steril 56:995–996PubMed
26.
Zurück zum Zitat Archer D, Fahy G, Viniegra-Sibal A, Anderson FD, Snipes W, Foldesy RG (1995) Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol 173:471–478PubMedCrossRef Archer D, Fahy G, Viniegra-Sibal A, Anderson FD, Snipes W, Foldesy RG (1995) Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol 173:471–478PubMedCrossRef
27.
Zurück zum Zitat Pouly JL, Bassil S, Frydman R et al (1996) Luteal support after in vitro fertilization: crinone 8 %, a sustained release vaginal progesterone gel, vs. utrogestan, an oral micronized progesterone. Hum Reprod 11:2085–2089PubMedCrossRef Pouly JL, Bassil S, Frydman R et al (1996) Luteal support after in vitro fertilization: crinone 8 %, a sustained release vaginal progesterone gel, vs. utrogestan, an oral micronized progesterone. Hum Reprod 11:2085–2089PubMedCrossRef
28.
Zurück zum Zitat Ng EHY, Miao B, Cheung W, Ho PC (2003) A randomized comparison of side effects and patient convenience of two vaginal progesterone formulations used for luteal support in in vitro fertilization cycles. Eur J Obstet Gynecol Reprod Biol 111:50–54PubMedCrossRef Ng EHY, Miao B, Cheung W, Ho PC (2003) A randomized comparison of side effects and patient convenience of two vaginal progesterone formulations used for luteal support in in vitro fertilization cycles. Eur J Obstet Gynecol Reprod Biol 111:50–54PubMedCrossRef
Metadaten
Titel
A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest® when used for luteal phase support in ICSI treatment
verfasst von
Malek-Mansour Aghsa
Haleh Rahmanpour
Maryam Bagheri
Fatemeh Davari-Tanha
Reza Nasr
Publikationsdatum
01.10.2012
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2410-7

Weitere Artikel der Ausgabe 4/2012

Archives of Gynecology and Obstetrics 4/2012 Zur Ausgabe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.